score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.1667	552.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61R (Missense)	1.0	MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat71		
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.S414L	0.1408	142.0	8e-06	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261													0				MPL p.S414L (Missense)		MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.1262	103.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.Q331* (Nonsense)		MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.E51K	0.1901	484.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135													0				ERRFI1 p.E51K (Missense)	0.0	MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R533Q	0.0924	119.0	8e-06	0.0																					0				RUNX1T1 p.R533Q (Missense)		MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.A337T	0.1095	137.0	0.0	0.0																					0				ESRP1 p.A337T (Missense)		MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G383S	0.0652	92.0	0.0	0.0																					0				COL1A1 p.G383S (Missense)		MEL-IPI_Pat71	MEL-IPI_Pat71-Tumor-SM-4DK2W	MEL-IPI_Pat71-Normal-SM-4NFW3
Biologically Relevant				Microsatellite Stability	Supporting variants		nan, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: nan, PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat71		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.869																									0				COSMIC Signature (version 2) 7 (87%)		MEL-IPI_Pat71		
